🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06509230
Recruiting Observational

Prediction of Significant Liver Fibrosis

NCT06509230 · tracked via the Priya Life Science China tracker
Sponsor
Huang Haijun
Phase
Observational
Started
2024-07-20
Last updated
2024-07-19

Condition(s) studied

Liver Fibrosis

Study summary

The deep learning method based on convolutional neural network (CNN) was used to extract the relevant features of liver fibrosis classification from the multi-modal information of digital pathological sections, clinical parameters and biomarkers of a large number of existing cases of liver puncture, and the U-Net architecture of CNN was used to segment and extract the features of clinical medical images.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age of 18-60 years old 2. The diagnosis of chronic hepatitis B is in line with the diagnostic criteria of China's 2019 Chronic Hepatitis B Prevention and Treatment Guidelines, and the diagnosis of non-alcoholic fatty liver is in line with the Asian Pacific Hepatology Association guidelines 3. Imaging showed no liver cancer Exclusion Criteria: 1. There are contraindications for liver biopsy 2. Liver pathology did not meet the criteria

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Haijun Huang Hangzhou Zhejiang Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06509230 on ClinicalTrials.gov ↗ ← All trials in China